These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 37100035)

  • 21. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
    Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
    J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis.
    Bakker DS; van der Wal MM; Heeb LEM; Giovannone B; Asamoah M; Delemarre EM; Drylewicz J; Nierkens S; Boyman O; de Bruin-Weller MS; Thijs JL; van Wijk F
    J Invest Dermatol; 2021 Aug; 141(8):1943-1953.e13. PubMed ID: 33610558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab for the treatment of adolescents with atopic dermatitis.
    Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
    Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study.
    Napolitano M; Fabbrocini G; Patruno C
    J Dermatol; 2023 Jul; 50(7):880-887. PubMed ID: 36914982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment.
    Napolitano M; Caiazzo G; Fabbrocini G; Balato A; Di Caprio R; Scala E; Scalvenzi M; Patruno C
    Br J Dermatol; 2021 Feb; 184(2):341-343. PubMed ID: 33533476
    [No Abstract]   [Full Text] [Related]  

  • 31. Alopecia areata-like and psoriasis after dupilumab use for atopic dermatitis.
    Maiolini VM; Sousa NA; Marsillac PF; Bressan AL
    An Bras Dermatol; 2021; 96(5):634-636. PubMed ID: 34274183
    [No Abstract]   [Full Text] [Related]  

  • 32. De novo pustular psoriasis associated with dupilumab therapy in a young male with the diagnosis of atopic dermatitis.
    Incel Uysal P; Gunhan O
    Dermatol Ther; 2022 May; 35(5):e15399. PubMed ID: 35194901
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
    Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
    J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of dupilumab in pediatric patients with a nummular phenotype of atopic dermatitis.
    Kim EJ; Hlobik M; Ho T
    Pediatr Dermatol; 2024; 41(3):455-457. PubMed ID: 38303143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of dupilumab-induced reverse psoriasis in a patient with atopic dermatitis.
    Fan J; Zhang L; Lu Y; Zhou P
    Dermatol Ther; 2022 Apr; 35(4):e15345. PubMed ID: 35094480
    [No Abstract]   [Full Text] [Related]  

  • 36. Dupilumab-induced psoriasis in a patient with atopic dermatitis and alopecia totalis: A case report and literature review.
    Flanagan KE; Pupo Wiss IM; Pathoulas JT; Walker CJ; Senna MM
    Dermatol Ther; 2022 Feb; 35(2):e15255. PubMed ID: 34877768
    [No Abstract]   [Full Text] [Related]  

  • 37. Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
    Salman A; Apti Sengun Ö; Aktas M; Taşkapan O
    Dermatol Ther; 2022 Jan; 35(1):e15192. PubMed ID: 34743366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atopic dermatitis 2017: where we were 10-15 years ago in psoriasis.
    No DJ; Amin M; Egeberg A; Thyssen JP; Wu JJ
    J Dermatolog Treat; 2018 Feb; 29(1):100-101. PubMed ID: 28604121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases.
    Kaufman BP; Alexis AF
    Curr Allergy Asthma Rep; 2018 Aug; 18(10):55. PubMed ID: 30171358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis.
    Nakazaki K; Yoshida M; Masamoto Y; Shinozaki-Ushiku A; Ikemura M; Hisamoto T; Yasunaga M; Sato S; Kurokawa M
    Int J Hematol; 2022 Sep; 116(3):446-452. PubMed ID: 35355217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.